Results 61 to 70 of about 30,146 (272)
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study [PDF]
, 2016 Background: Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related mortality in children.Buijs-Gladdines, J.G.C.A.M. (Jessica), Buijsman, R.C., Canté-Barrett, K. (Kirsten), Dinjens, W.N.M. (Winand), Horstmann, M.A. (Martin), Kuiper, R.P. (Roland), Li, Y. (Yunlei), Marion, R. (Ronald) van, Meijerink, J.P.P. (Jules), Pieters, R. (Rob), Smits, W.K., Spek, P.J. (Peter) van der, Stubbs, A.P. (Andrew), Vroegindeweij, E.M. (Eric), Zaman, G.J.R. +14 morecore +1 more sourceAmerican College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Arthritis &Rheumatology, EarlyView.Objective
Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.Arsene Mekinian, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heilblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson +111 morewiley +1 more sourceTuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
Infection and Drug Resistance, 2020 Emiko Sakiyama, Yoshiaki Chinen, Taku Tsukamoto, Tomoko Takimoto-Shimomura, Saeko Kuwahara-Ota, Yayoi Matsumura-Kimoto, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Junya Kuroda Division of Hematology and Oncology, Department of Medicine, Kyoto ...Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J +9 moredoaj Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study
Arthritis &Rheumatology, EarlyView.Objective
The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods
This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian +35 morewiley +1 more sourceADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
Blood Advances: Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic response. ADORE was David M. Ross, Florian H. Heidel, Andrew Charles Perkins, Andreas Reiter, Carl Crodel, Caroline Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Jagannath Kota, Anirudh Prahallad, Monika Wroclawska, Min Lu, Claire N. Harrison +22 moredoaj +1 more sourceLinezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Arthritis &Rheumatology, Accepted Article.Background
Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Since mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...Xuezhi Hong, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea‐Hermina Györfi, Yi‐Nan Li, Meilin Xu, Langxian Zhi, Thuong Trinh‐Minh, Clara Dees, Georg Schett, Jörg H.W. Distler, Alexandru‐Emil Matei +13 morewiley +1 more sourceA pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Haematologica, 2015 Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies.Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek +14 moredoaj +1 more sourceMARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. [PDF]
, 2015 Work in the Green lab is supported by
Leukemia and Lymphoma Research, Cancer Research UK, the NIHR Cambridge
Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre,
and the Leukemia and Lymphoma Society of America.A Tefferi, A Tefferi, Claire N. Harrison, E Puigdecanet, F Passamonti, H Yoshida, J Nangalia, John T. Reilly, M Michalak, M Wictome, P Guglielmelli, R Rampal, S Schwemmers, S Verstovsek, S Verstovsek, T Klampfl +15 morecore +1 more source
